Cardinal Health is aiming for 13 to 15 percent adjusted EPS growth in fiscal 2027, driven by momentum in its specialty segment and investments in oncology, urology, and autoimmune care.
North Carolina’s life sciences sector is taking a measured approach to growth, favoring smaller, risk-managed deals and targeted expansions, while a few major players make billion-dollar commitments.
Certara is betting that catching data standard problems at the source can save clinical trial sponsors months of costly remediation and regulatory headaches.
